Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 275

“Chronic Lymphocytic Leukemia: Opportunity Analysis and Forecasts to 2027”

Posted by fidest press agency su mercoledì, 22 maggio 2019

Chronic lymphocytic leukemia (CLL) is a form of cancer that originates from lymphocytes in the bone marrow and later invades the blood and/or lymphoid tissues. CLL treatment has been transformed since the novel oral targeted agents Imbruvica (ibrutinib), Zydelig (idelalisib), and Venclexta (venetoclax) were introduced to the market from 2014 onwards and challenged the prior dominance of chemoimmunotherapy regimens. During the forecast period, the global CLL market will welcome five new drugs-Calquence (acalabrutinib), zanubrutinib, umbralisib, ublituximab, and Revlimid (lenalidomide).It is estimated that the value of the CLL market in the 7MM (US, France, Germany, Italy, Spain, UK, and Canada) in 2017 was $7.7B. Among these sales, 79.5% ($6.1B) were generated in the US, with the 5EU representing the next largest region by sales, with an estimated 18.5% ($1.4B). Canada contributed the smallest proportion of sales, at 2.0% ($157M) of the global CLL market. By 2027, the US is forecast to represent a similar proportion of the 7MM sales, at 79.6%. The 5EU and Canada will account for 18.3% and 2.0% of the 7MM CLL market, respectively.It is projected that the CLL sales will rise to $9.2B in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Canada) by 2027, at a modest compound annual growth rate (CAGR) of 1.8%. In particular, US CLL market is expected to grow more rapidly than the 5EU or Canada, increasing to $7.4B by 2027, at a still-modest CAGR of 1.9%. Sales in the other regions are also expected to increase by the end of the forecast period, with the 5EU and Canada having a CAGR of 1.7% and 1.8%, respectively.
This is driven by increasing incidence, driven primarily by aging populations, label expansions into the first-line setting for AbbVie/Roche’s Venclexta, frontline approval of the combination of AbbVie/Johnson & Johnson’s Imbruvica + Venclexta, and the increasing use of combination therapies instead of monotherapies or chemoimmunotherapy regimens. Generic and biosimilar erosion of some of the mainstays of CLL treatment is also expected during the forecast period, particularly the use of generic ibrutinib and biosimilar rituximab will lead to a decline in sales. A lack of innovative drugs in the late-stage pipeline with novel mechanisms of action means that next-generation agents are not expected to generate significant sales.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: